PMID- 37215857
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230523
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Electronic)
IS  - 2405-8440 (Linking)
VI  - 9
IP  - 5
DP  - 2023 May
TI  - Anti-inflammatory and anti-allergic effects of Cheonwangbosim-dan water extract: 
      An in vitro and in vivo study.
PG  - e16172
LID - 10.1016/j.heliyon.2023.e16172 [doi]
LID - e16172
AB  - ETHNOPHARMACOLOGICAL RELEVANCE: Cheonwangbosim-dan is a traditional herbal 
      prescription that is widely used to improve or treat physical and mental 
      illnesses in East Asian countries.Aim of the study: The aim of the present study 
      was to investigate the preventive and protective effects of a Cheonwangbosim-dan 
      water extract (CBDW) against allergic inflammation using in vitro and in vivo 
      models. MATERIALS AND METHODS: BEAS-2B and MC/9 cells were treated with various 
      concentrations of CBDW and stimulated with different inducers of inflammatory 
      mediators. The production of various inflammatory mediators was subsequently 
      evaluated. BALB/c mice were sensitized and challenged by repeated application of 
      ovalbumin (OVA). CBDW was administered by oral gavage once daily for 10 
      consecutive days. We assessed the number of inflammatory cells and production of 
      Th2 cytokines in bronchoalveolar lavage fluid (BALF), the plasma levels of total 
      and OVA-specific immunoglobulin E (IgE), and histological changes in lung tissue. 
      RESULTS: Our findings showed that CBDW significantly decreased the levels of 
      various inflammatory mediators (eotaxin-1, eotaxin-3, RANTES, LTC(4), TNF-alpha, 
      MMP-9, 5-LO, ICAM-1, and VCAM-1) in vitro, significantly reduced the accumulation 
      of total inflammatory cells, the production of Th2 cytokines (IL-5 and IL-13), 
      the levels of IgE (total and OVA-specific) in vivo, and remarkably inhibited 
      histological changes (infiltration of inflammatory cells and goblet cell 
      hyperplasia) in vivo. CONCLUSIONS: These results suggest that CBDW possesses 
      anti-inflammatory and anti-allergic properties by lowering allergic inflammation.
CI  - (c) 2023 The Authors. Published by Elsevier Ltd.
FAU - Jeon, Woo-Young
AU  - Jeon WY
AD  - KM Convergence Research Division, Korea Institute of Oriental Medicine, 1672 
      Yuseong-daero, Yuseong-gu, Daejeon, 34054, Republic of Korea.
FAU - Jin, Seong Eun
AU  - Jin SE
AD  - KM Science Research Division, Korea Institute of Oriental Medicine, 1672 
      Yuseong-daero, Yuseong-gu, Daejeon, 34054, Republic of Korea.
FAU - Sohn, Eunjin
AU  - Sohn E
AD  - KM Convergence Research Division, Korea Institute of Oriental Medicine, 1672 
      Yuseong-daero, Yuseong-gu, Daejeon, 34054, Republic of Korea.
FAU - Jo, Kyuhyung
AU  - Jo K
AD  - KM Convergence Research Division, Korea Institute of Oriental Medicine, 1672 
      Yuseong-daero, Yuseong-gu, Daejeon, 34054, Republic of Korea.
FAU - Ha, Hyekyung
AU  - Ha H
AD  - KM Science Research Division, Korea Institute of Oriental Medicine, 1672 
      Yuseong-daero, Yuseong-gu, Daejeon, 34054, Republic of Korea.
FAU - Shin, Hyeun-Kyoo
AU  - Shin HK
AD  - KM Science Research Division, Korea Institute of Oriental Medicine, 1672 
      Yuseong-daero, Yuseong-gu, Daejeon, 34054, Republic of Korea.
FAU - Lee, Mee-Young
AU  - Lee MY
AD  - KM Convergence Research Division, Korea Institute of Oriental Medicine, 1672 
      Yuseong-daero, Yuseong-gu, Daejeon, 34054, Republic of Korea.
LA  - eng
PT  - Journal Article
DEP - 20230511
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC10199208
OTO - NOTNLM
OT  - Airway inflammation
OT  - Allergic asthma
OT  - Anti-Allergic
OT  - Anti-Inflammatory
OT  - Cheonwangbosim-dan
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2023/05/22 19:11
MHDA- 2023/05/22 19:12
PMCR- 2023/05/11
CRDT- 2023/05/22 12:31
PHST- 2022/11/01 00:00 [received]
PHST- 2023/04/23 00:00 [revised]
PHST- 2023/05/08 00:00 [accepted]
PHST- 2023/05/22 19:12 [medline]
PHST- 2023/05/22 19:11 [pubmed]
PHST- 2023/05/22 12:31 [entrez]
PHST- 2023/05/11 00:00 [pmc-release]
AID - S2405-8440(23)03379-0 [pii]
AID - e16172 [pii]
AID - 10.1016/j.heliyon.2023.e16172 [doi]
PST - epublish
SO  - Heliyon. 2023 May 11;9(5):e16172. doi: 10.1016/j.heliyon.2023.e16172. eCollection 
      2023 May.